Exploratory calcineurin inhibitor-free regimens in living-related kidney transplant recipients

Brazilian Journal of Medical and Biological Research

Volumn 40, Issue 4, 2007, Pages 457-465

  Garcia R ^a   Machado, P G ^a   Felipe, C R ^a   Park, S I ^a   Spinelli, G A ^a   Franco, M F ^a   Tedesco Silva, Helio ^a,b   Medina Pestana, J O ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Acute rejection; Clinical trial; Kidney transplantation; Mycophenolate mofetil; Sirolimus; Tacrolimus

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DEATH; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FEMALE; GLUCOSE BLOOD LEVEL; GRAFT FAILURE; GRAFT SURVIVAL; HAPLOTYPE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTHESIS; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LIVER FUNCTION TEST; LIVING DONOR; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEGRO; PATIENT CARE; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

CYTOMEGALOVIRUS;

EID: 34247216260     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2007000400003     Document Type: Article

References (16)

1. Siddiqi N, McBride MA, Hariharan S. Similar risk profiles for post-transplant renal dysfunction and long-term graft failure: UNOS/OPTN database analysis. Kidney Int 2004; 65: 1906-1913.
2. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation 2002; 74: 1377-1381.
3. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311-318.
4. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291-1295.
5. Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282-1287.
6. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74: 1560-1567.
7. Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809-817.
8. Abramowicz D, Manas D, Lao M, Venrenterghem Y, del Castillo D, Wijngaard P, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002; 74: 1725-1734.
9. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, Hoitsma AJ, Hene RJ, Weimar W, et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13: 1365-1373.
10. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-1076.
11. ter Meulen CG, Baan CC, Hene RJ, Hilbrands LB, Hoitsma AJ. Two doses of daclizumab are sufficient for prolonged interleukin-2Ralpha chain blockade. Transplantation 2001; 72: 1709-1710.
12. Di Marco GS, de Andrade MC, Felipe CR, Alfieri F, Gooding A, Silva HT Jr, et al. Determination of sirolimus blood concentration using high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit 2003; 25: 558-564.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
14. Vincenti F, Pace D, Birnbaum J, Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant 2003; 3: 50-52.
15. Mourad M, Wallemacq P, Konig J, de Frahan EH, Eddour DC, De Meyer M, et al. Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary? Clin Pharmacokinet 2002; 41: 319-327.
16. Ferreira AN, Machado PG, Felipe CR, Motegi SA, Hosaka BH, Tanaka MK, et al. Concentration-controlled use of sirolimus associated with reduced exposure of cyclosporine in black recipients of primarily living renal allograft donors: 12-month results. Clin Transplant 2005; 19: 607-615.